Recent Updates — ELTP

On October 28, 2026, the Board of Directors increased its size from four to six members and unanimously elected Aqeel A. Fatmi, Ph.D., and John W. LaRocca, Esq. as Class II and Class I directors, respectively. Dr. Fatmi brings over four decades of pharmaceutical industry experience, including roles at Patheon Inc. and Banner Life Sciences, while Mr. LaRocca offers more than three decades of legal expertise in the generic drug sector, having served as General Counsel for Y-mAbs Therapeutics and Aerie Pharmaceuticals. Both directors will serve until the next annual meeting and receive standard non-management director compensation. Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products.

Elite Pharmaceuticals, Inc. filed a Form 10-Q for the first quarter ended June 30, 2027, and issued a press release announcing financial results on August 13, 2026. Consolidated revenues decreased 19.5% to $32.4 million from $40.3 million in the prior year period, primarily due to lower margins on its generic Vyvanse product line amid competitive market adjustments. Income from operations fell 65% to $7.5 million, while net income attributable to common shareholders was $5.9 million. Management will host a conference call on August 14, 2026, at 11:30 AM EDT to discuss the results and provide a business update. Elite Pharmaceuticals is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic oral drug products.